ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)–infected Participants With HIV-1 RNA
Sign Up to like & getrecommendations! Published in 2018 at "Clinical Infectious Diseases"
DOI: 10.1093/cid/cix1083
Abstract: Background Limited data exist on initial human immunodeficiency virus type 1 (HIV-1) treatment with dolutegravir plus lamivudine. Methods A5353 is a phase 2, single-arm, pilot study of once-daily dolutegravir (50 mg) plus lamivudine (300 mg)… read more here.
Keywords: 500000 copies; treatment; plus lamivudine; hiv rna ... See more keywords